Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans

Thrombosis and Haemostasis

Volumn 85, Issue 3, 2001, Pages 482-487

  Schick, B P ^a   Gradowski, J F ^a   San Antonio, J D ^a   Martinez, J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Danaparoid; Heparin; Lovenox; Low molecular weight heparin; Orgaran; Peptide; Reversal of anticoagulation; Serglycin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; DANAPAROID; ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PEPTIDE; PROTAMINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; ASSAY; BLEEDING; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSAL REACTION; SERODIAGNOSIS; SUBSTITUTION THERAPY; TREATMENT OUTCOME;

EID: 0035080696     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615609     Document Type: Article

References (27)

1. Poor reversal of low molecular weight heparin by protamine
2. Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons
3. The effect of protamine sulfate on plasma tissue factor pathway inhibitor release by intravenous and subcutaneous unfractionated and low molecular weight heparin in man
4. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man
5. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation
6. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass
7. Sequestration of platelets in the pulmonary circulation as a consequence of protamine reversal of the anticoagulant effects of heparin
8. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction
9. The use of low molecular weight heparin in pediatric patients: A prospective cohort study
10. The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with Factor V Leiden mutation
11. Postthrombotic syndrome after hip or knee arthroplasty - A cross-sectional study
12. The emerging role of low-molecular-weight heparin and anti-platelet therapies in the cardiac catheterization laboratory
13. Anticoagulant treatment of thromboembolism with intravenous heparin therapy in the early postoperative period following total joint arthroplasty
14. A novel protamine variant reversal of heparin anticoagulation in human blood in vitro
15. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model
16. A [+18RGD]protamine variant for nontoxic and effective reversal of conventional heparin and low molecular weight heparin anticoagulation
17. Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine
18. Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogs
19. Design and synthesis of a helix heparin-binding peptide
20. Structure-function relations of antithrombin III-heparin interactions as assayed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes
21. Development of heparin antagonists with focused biological activity
22. A heparin-binding synthetic peptide of heparin/heparan sulfate-interacting protein modulates blood coagulation activities
23. Molecular modeling of protein-glycosaminoglycan interactions
24. Design of peptides with high affinities for heparin and endothelial cell proteoglycans
25. Orgaran (Org 10172): Its pharmacologic profile in experimental models
26. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III
27. Low-affinity material does not contribute to the antithrombotic activity of Orgaran in human plasma